Repeated at 12:15 pm, Cherkasky Auditorium, Montefiore Medical Center
Dr. Grover Bagby has authored more than 130 primary research papers and 50 books, chapters, and editorials, largely in the field of hematopoiesis and hematopoietic abnormalities in a variety of diseases. Currently the Director of the Molecular Hematology Training Program at OHSU, Dr. Bagby is committed to clinical teaching and translational research training and focuses his own investigative attention on developing a clear molecular understanding of how bone marrow injury leads to myelodysplasia and acute leukemia.
Dr. Bagby has been elected to AOA, Amer. Soc. Of Clinical Investigation, Association of American Physicians, President of the International Society for Experimental Hematology, and Master of the American College of Physicians. For more than 33 years he has served as a member or chair of various NIH scientific review groups and is currently a member of the Board of Scientific Counselors of the National Heart Lung and Blood Institute. He has served as a member and chair of multiple committees of the American Society of Hematology and has served as a member of the Hematology Committee of the American Board of Internal Medicine. He has recently completed a 10 year term as Associate Editor of the journal Blood and has served for 23 years as Chair of the Scientific Advisory Board of the Fanconi Anemia Research Fund.
A graduate of Pomona College and Baylor College of Medicine, Dr. Bagby completed his fellowship training in Hematology at Oregon Health and Sciences University (OHSU) and began to conduct laboratory research studies on myelodysplasia and acute myelogenous leukemia studies that have been continuously funded by investigator initiated grant support for the past 36 years. In 1984 he became Chief of the Division of Hematology/Oncology at the Portland VA Medical Center and in 1985, Chief of Hematology and Medical Oncology at OHSU. In 1992 he was appointed founding Director of the Cancer Center at OHSU (now the Knight Cancer Institute), a center that within 5 years had received formal Cancer Center designation by the National Cancer Institute and is now Directed by Dr. Brian Druker, one of Dr. Bagby’s first recruits to OHSU.
Objectives - After attending this activity, participants will be able to:
- To review the clinical features and pathogenesis of acquired and hereditary bone marrow failure
- To review the clinical and laboratory manifestations of Fanconi anemia
- To review current understanding of myelodysplasia and acute leukemia pathogenesis in Fanconi anemia and to clarify that the process informs our understanding of more commonly occurring sporadic leukemias
Accreditation: Albert Einstein College of Medicine designates this educational activity for a maximum of 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.